Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• Prostate adenocarcinoma (PCa) and melanoma show differential sensitivity to immune checkpoint blockade (ICB) therapies targeting T lymphocytes.
• A significant portion of melanoma patients (approx. 40%) exhibit resistance or develop acquired resistance to ICB.
• Key differences in tumor microenvironments include scanty cytotoxic T cell infiltrate in PCa and pronounced immune suppression in ICB-resistant melanoma.

Purpose of the Study:

• To compare the tumor microenvironment in PCa and ICB-resistant melanoma.
• To focus on major immune checkpoint molecules: cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed death-1 (PD-1), lymphocyte activation gene-3 (LAG-3), and T cell immunoglobulin and mucin-domain containing-3 (TIM-3).
• To identify strategies for overcoming ICB resistance.

Main Methods:

• Comparative analysis of tumor microenvironments in PCa and ICB-resistant melanoma.
• Examination of key immune checkpoint molecule expression and function.
• Investigation of crosstalk between cancer and immune cells mediated by inhibitory immune checkpoints.

Main Results:

• Characterization of distinct immune microenvironments in PCa and ICB-resistant melanoma.
• Identification of specific immune checkpoint molecules (CTLA-4, PD-1, LAG-3, TIM-3) involved in therapeutic resistance.
• Elucidation of immune cell crosstalk mechanisms driven by inhibitory checkpoints.

Conclusions:

• The study provides insights into the immune microenvironmental differences between PCa and ICB-resistant melanoma.
• Understanding these differences and immune checkpoint roles is crucial for developing effective ICB therapies.
• Identified strategies hold promise for overcoming ICB resistance in both PCa and melanoma patients.